A spinout that stopped sounding like a paper
We rebuilt the founder's public record around the problem the technology solves rather than the method behind it, which opened investor conversations and two clinical evaluation sites.
- 6
- investor conversations
- 2
- clinical evaluation sites
- 1
- non dilutive award
Strong science, a young spinout, and a founder whose public explanation of the company still read like a methods section.
We separated the scientific record from the commercial argument, gave the founder a plain claim about the problem being solved, and published the reasoning behind it.
Six investor conversations, two clinical evaluation sites agreed, and a non dilutive award that cited the public case for the work.
- A commercial claim stated separately from the science.
- Founder writing aimed at investors and clinicians, not at reviewers.
- Evaluation sites approached with a clear evidence plan.
- Academic credibility kept intact and used as an asset.
Cited by peers, invisible to industry. Two advisory agreements later, the balance changed.
The science was competitive. The programme was invisible to everyone deciding where money goes.
Sixty applications, four replies. Then the approaches started arriving instead.